CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Metabolix, Inc. (NASDAQ: MBLX), a bioscience company focused on
developing clean, sustainable solutions for plastics, chemicals and
energy, today announced that it has appointed Matthew Strobeck, Ph.D.,
to its board of directors. Dr. Strobeck, who previously served on the
Metabolix board of directors from 2006 to 2011, brings with him
financial expertise and a deep understanding of the biotechnology
industry. The appointment is effective as of March 1, 2012.
"With his background as a life science investor and previous experience
on the Metabolix board of directors, Matthew is uniquely suited to
provide valuable perspectives and insights that will help drive the
Company's future success," said Richard P. Eno, president and CEO of
Metabolix. "We plan to leverage his expertise to help manage our
portfolio of technology and product offerings and to optimize the
integration of our financial and business strategy."
From June 2008 to October 2011, Dr. Strobeck was a partner, member of
the management committee and member of the advisory board of Westfield
Capital Management, an investment firm based in Boston. Dr. Strobeck
received a B.S. from St. Lawrence University, a Ph.D. from the
University of Cincinnati, an S.M. from the Harvard University-MIT Health
Sciences Technology Program and an S.M. from the MIT Sloan School of
Management.
Dr. Strobeck commented, "With a unique technology platform in PHA
biopolymers, deep scientific expertise and significant customer-facing
market experience, Metabolix is well positioned to help shape a
promising future for biomaterials. I look forward to re-joining the
board of directors and working with Metabolix to capture the significant
commercial opportunity in providing differentiated, sustainable
alternatives to conventional plastics and chemicals produced from fossil
fuel."
About Metabolix
Founded in 1992, Metabolix, Inc. is an innovation-driven bioscience
company focused on providing sustainable solutions for the world's needs
for plastics, chemicals and energy. The Company is taking a systems
approach, from gene to end product, integrating sophisticated
biotechnology with advanced industrial practice. Metabolix is developing
biosourced industrial chemicals and plastics, as well as a proprietary
platform technology for co-producing plastics, chemicals and energy,
from crops.
For more information, please visit www.metabolix.com.
(MBLX-G)
Safe Harbor for Forward-Looking Statements
This press release contains forward-looking statements which are made
pursuant to the safe harbor provisions of Section 27A of the Securities
Act of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. The forward-looking statements in this release do
not constitute guarantees of future performance. Investors are cautioned
that statements in this press release which are not strictly historical
statements, including, without limitation, statements regarding Dr.
Strobeck's potential contribution to Metabolix, expectations for
commercialization of Metabolix products and technology, and optimizing
the integration of our financial and business strategy, constitute
forward-looking statements. Such forward-looking statements are subject
to a number of risks and uncertainties that could cause actual results
to differ materially from those anticipated and are detailed in
Metabolix's filings with the Securities and Exchange Commission.
Metabolix assumes no obligation to update any forward-looking
information contained in this press release or with respect to the
announcements described herein.
Media:
Metabolix
Lynne Brum, 617-682-4693
LBrum@metabolix.com
or
Schwartz
MSL
Keith Giannini or Kirsten Swenson, 781-684-0770
metabolix@schwartzMSL.com
or
Investors:
ICR
James
Palczynski, 203-682-8229
james.palczynski@icrinc.com
Source: Metabolix, Inc.
News Provided by Acquire Media